BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.
Nasdaq Turns Lower; Crude Oil Rises Sharply
U.S. stocks pared gains toward the end of trading, with the Nasdaq Composite turning lower on Thursday.
BTIG Downgrades Magenta Therapeutics to Neutral
BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.
Related Posts
New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies
Healthcare company Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) completed its previously announced acquisition of Zynerba Pharmaceuticals, Inc.
Mohawk Industries Q1 Earnings Exceed Expectations
Mohawk Industries Inc (NYSE:MHK) reported Q1 2023 revenues of $2.81 billion, down 6.9% Y/Y, exceeding the consensus of $2.50 billion.…
Why 5 Twilio Analysts Are Slashing Price Targets After Earnings
Shares of Twilio Inc (NYSE: TWLO) Thursday tumbled on disappointing quarterly revenue and projections.
BofA Securities On Twilio